FORTIS
Fortis Healthcare Limited
NSELast Traded Price
₹928.45
-24.15 (-2.51%)
Open
₹962.5
High
₹967.3
Low
₹920
Prev Close
₹960.9
Industry
Hospital
Market Cap
70720.70 Cr
Filing History
Recent corporate announcements and filings for FORTIS
Business Update
Positive
2026-05-29 16:20
Fortis Healthcare reported a steady performance in FY26 with improved consolidated operating EBITDA margins at 22.8% (up from 20.4% in FY25) and hospital business operating EBITDA margins at 22.2% (up from 20.5% in FY25). A dividend of INR1 per share was recommended. The company added approximately 800 beds in FY26 through brownfield expansion and acquisitions, with a Capex of INR700 crores. Management guided for 15%+ revenue growth and 150 basis points EBITDA margin improvement for the hospital business in FY27, targeting 25% EBITDA margin by FY28 with 1.5-2% YoY improvement. Diagnostic business (Agilus) is expected to achieve 23-24% EBITDA margins and double-digit revenue growth in FY27, driven by 5% volume growth. The company plans to add ~1,800 beds over the next four years, including ~400 beds in FY27, with annual Capex of ~INR900 crores. IHH plans to increase its stake to 50% with INR10,000 crores equity infusion for growth. Occupancy dip in some hospitals attributed to international business and onco drug capping is being addressed by seeking alternate business opportunities.
Business Update
Neutral
2026-05-25 20:46
Fortis Healthcare Limited has announced the availability of the audio recording of the investors/analysts meet held on May 25, 2026. The meeting discussed the company's Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026, and the recording is accessible on the company's website.
Financials
Negative
2026-05-22 21:09
CRITICAL RED FLAG DETECTED
Fortis Healthcare Limited reported Q4 FY26 consolidated Revenue of ₹2,364.67 Cr vs ₹2,007.20 Cr (▲17.81% YoY), EBITDA of ₹542.94 Cr vs ₹459.91 Cr (▲18.05% YoY), and PAT of ₹271.19 Cr vs ₹188.02 Cr (▲44.23% YoY). EBITDA Margin was 22.96% vs 22.91% (▲5bps). The Board recommended a final dividend of ₹1/- per equity share for FY 2025-26. The auditor's report highlights an ongoing SFIO investigation into alleged improper transactions and non-compliances, and a Supreme Court order for considering a forensic audit related to past transactions concerning RHT Health Trust.
Routine
Neutral
2026-05-22 20:56
New Filing detected. See link for details.
Financials
Neutral
2026-05-22 20:52
CRITICAL RED FLAG DETECTED
Consolidated Revenue for Q4 FY26 was ₹2,364.67 Cr (up 17.8% YoY), EBITDA was ₹538.55 Cr (up 22.4% YoY), and PAT was ₹271.19 Cr (up 44.2% YoY). EBITDA Margin expanded by 85 bps to 22.77%. The Board recommended a final dividend of ₹1/- per equity share for FY26. Auditors highlighted an ongoing SFIO investigation and a Supreme Court order regarding alleged improper transactions and non-compliances, though their opinion on the financial results was unmodified.
Financials
Positive
2026-05-22 20:48
CRITICAL RED FLAG DETECTED
The company reported strong consolidated financial results for the quarter ended March 31, 2026. Consolidated Revenue stood at ₹2,364.67 Cr versus ₹2,007.20 Cr (▲17.8% YoY), EBITDA at ₹530.45 Cr versus ₹406.34 Cr (▲30.6% YoY), and PAT at ₹271.19 Cr versus ₹188.02 Cr (▲44.2% YoY). EBITDA Margin expanded from 20.24% to 22.43% (▲219bps). The Board also recommended a final dividend of ₹1/- per equity share for the financial year 2025-26. Auditors issued an unmodified opinion on the financial results.
Financials
Positive
2026-05-22 20:32
Consolidated Revenue ₹2,365Cr vs ₹2,007Cr (▲17.8% YoY), EBITDA ₹531Cr vs ₹435Cr (▲22.2% YoY), PAT ₹271Cr vs ₹188Cr (▲44.2% YoY). EBITDA Margin 22.5% vs 21.7% (▲80bps). The Board also recommended a dividend of INR 1 per share (10% of Face Value).
Financials
Negative
2026-05-22 20:24
CRITICAL RED FLAG DETECTED
Consolidated Revenue ₹2364.67 Cr vs ₹2007.20 Cr (▲17.81% YoY), EBITDA ₹526.06 Cr vs ₹386.54 Cr (▲36.08% YoY), PAT ₹271.19 Cr vs ₹188.02 Cr (▲44.23% YoY). EBITDA Margin 22.25% vs 19.26% (▲299bps). The company also recommended a final dividend of ₹1 per equity share. The audit report highlights an ongoing Serious Fraud Investigation Office (SFIO) investigation regarding alleged improper transactions and non-compliances.
Financials
Positive
2026-05-22 20:11
CRITICAL RED FLAG DETECTED
Consolidated Revenue ₹2,364.67 Cr vs ₹2,007.20 Cr (▲17.8% YoY), EBITDA ₹526.06 Cr vs ₹386.54 Cr (▲36.1% YoY), PAT ₹271.19 Cr vs ₹188.02 Cr (▲44.2% YoY). EBITDA Margin 22.25% vs 19.26% (▲299bps). The company also recommended a final dividend of ₹1/- per equity share for FY 2025-26. The auditor's report noted ongoing SFIO investigations and a Supreme Court order for a potential forensic audit regarding past transactions, though their opinion on the financial results was unmodified.
Financials
Negative
2026-05-22 20:07
CRITICAL RED FLAG DETECTED
Consolidated Revenue ₹2,364.67 Cr vs ₹2,007.20 Cr (▲17.81% YoY), EBITDA ₹536.72 Cr vs ₹455.27 Cr (▲17.89% YoY), PAT ₹271.19 Cr vs ₹188.02 Cr (▲44.23% YoY). EBITDA Margin 22.71% vs 22.68% (▲3bps).
Financials
Neutral
2026-05-15 17:19
Fortis Healthcare Limited announced an investors/analysts conference call to discuss the Company's Q4FY26 and Full Year FY26 audited financial results. The call is scheduled for Monday, May 25, 2026, at 11:00 am (IST).
Business Update
Neutral
2026-04-29 13:49
Fortis Healthcare, referencing an announcement by IHH Healthcare Berhad, disclosed an update on the material litigation between its promoter, Northern TK Venture Pte Ltd, and Daiichi Sankyo Company Limited. The Tokyo District Court has concluded the preparatory and oral proceedings for NTK's claim, with the judgment scheduled for September 10, 2026.
Business Update
Positive
2026-04-23 14:09
Fortis Healthcare Limited's Nomination & Remuneration Committee approved the grant of up to 1,32,05,200 employee stock options under its ESOP Scheme 2026. The options have an exercise price of INR 923.10 per option and are granted to eligible employees.
Business Update
Neutral
2026-04-22 17:09
Fortis Healthcare will hold in-person investor/analyst meetings (Non Deal Roadshow) on April 27th and 28th, 2026, in Mumbai, organized by JM Financial. The meetings will cover general business updates and industry discussions.
Business Update
Neutral
2026-04-22 17:07
Fortis Healthcare will hold an investor/analyst Non Deal Roadshow in Mumbai on April 27-28, 2026, organized by JM Financial, to discuss general business updates and industry trends. No UPSI will be shared.
Routine
Positive
2026-04-10 12:49
Fortis Healthcare filed its FY26 disclosure for corporate bonds/debentures. The credit rating for these instruments was upgraded by CRISIL from AA to AA+. All interest payments due on December 22, 2025, were made on time, with no reported defaults.
Routine
Neutral
2026-04-08 18:33
New Filing detected. See link for details.
Routine
Neutral
2026-04-08 16:26
Fortis Healthcare Limited submitted certificates under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. KFin Technologies Limited, the Registrar and Transfer Agent, certified the details of securities dematerialized/rematerialized during the period.
Routine
Neutral
2026-04-01 11:04
New Filing detected. See link for details.
Business Update
Negative
2026-03-28 14:12
CRITICAL RED FLAG DETECTED
Fortis Healthcare's subsidiary, Fortis Hospitals Limited, received an Income Tax Order dated March 27, 2026, for AY 2024-25, raising a demand of INR 117.04 Crores. The company is evaluating all options including filing an appeal against the order.
Routine
Neutral
2026-03-25 15:59
Fortis Healthcare Limited announced the closure of its trading window for dealing in company shares from April 1, 2026, until 48 hours after the declaration of Audited Financial Results for the quarter and financial year ended March 31, 2026, to prevent insider trading.
Governance
Positive
2026-03-18 22:29
Fortis Healthcare Limited shareholders approved the Fortis Healthcare Limited Employees Stock Option Scheme 2026 and the grant of stock options to eligible employees of its subsidiary and associate companies with requisite majority via postal ballot dated March 18, 2026.
Governance
Positive
2026-03-18 22:24
Fortis Healthcare Limited announced the results of its postal ballot on March 18, 2026. Shareholders approved with requisite majority the Fortis Healthcare Limited Employees Stock Option Scheme 2026 and the grant of employee stock options to eligible employees of its subsidiary and associate companies under the scheme.
Business Update
Positive
2026-03-02 02:00
Fortis Healthcare Limited filed the certified NCLT order for a composite scheme of merger by absorption of its wholly-owned subsidiaries (FESL, FCCL, FHMEL, B&B) with Fortis Hospitals Limited. The scheme became effective on March 1, 2026.
Financials
Positive
2026-02-20 13:14
Consolidated Revenue ₹2,265Cr vs ₹1,928Cr (▲17.5% YoY), EBITDA ₹505Cr vs ₹375Cr (▲34.8% YoY), PAT ₹197Cr vs ₹250Cr (▼21.2% YoY). EBITDA Margin 22.3% vs 19.4% (▲290bps). PAT decline due to one-off exceptional loss of ₹46Cr.
Business Update
Negative
2026-02-19 16:50
Fortis Healthcare announced an update on material litigation where its promoter, Northern TK Venture, filed an amended petition against Daiichi Sankyo for tortious losses of over INR 109 billion and defamation, also seeking injunctions to prevent obstruction of Fortis and Malar share acquisitions.
Business Update
Neutral
2026-02-16 22:48
Fortis Healthcare announced the audio recording of the investor/analyst meet held on February 16, 2026, is available. The meet discussed unaudited Q3 FY26 standalone and consolidated financial results for the quarter ended December 31, 2025.
Governance
Positive
2026-02-16 22:21
Fortis Healthcare Limited is seeking shareholder approval via postal ballot for its ESOP 2026, including granting up to 1,50,99,163 options to employees of the company, subsidiaries, and associates. The e-voting period is from Feb 17 to March 18, 2026.
Governance
Positive
2026-02-16 22:18
Fortis Healthcare will conduct a postal ballot for shareholder approval of the Fortis Healthcare Limited Employees Stock Option Scheme 2026, including granting options to employees of the company, subsidiaries, and associates. E-voting runs from February 17 to March 18, 2026.
Financials
Negative
2026-02-13 20:02
CRITICAL RED FLAG DETECTED
Board approved Q3 FY26 Un-Audited Consolidated and Standalone Financial Results, Fortis Healthcare Limited ESOP 2026, and revised Related Party Transaction Policy. The audit report notes ongoing SFIO/EOW investigations and a Supreme Court directive for forensic audits.
Financials
Positive
2026-02-13 19:18
Consolidated Revenue ₹2,265Cr vs ₹1,928Cr (▲17.5% YoY), Operating EBITDA ₹505Cr vs ₹375Cr (▲34.8% YoY), PAT ₹197Cr vs ₹254Cr (▼22.4% YoY, impacted by exceptional items). EBITDA Margin 22.3% vs 19.4% (▲290bps).
Financials
Positive
2026-02-13 19:15
Consolidated Revenue ₹2,265Cr vs ₹1,928Cr (▲17.5% YoY), Operating EBITDA ₹505Cr vs ₹375Cr (▲34.8% YoY), PAT (excl. exceptional) ₹243Cr vs ₹230.2Cr (▲5.6% YoY). EBITDA Margin 22.3% vs 19.4% (▲290bps).
Financials
Negative
2026-02-13 18:53
CRITICAL RED FLAG DETECTED
Fortis Healthcare announced its Q3 FY26 unaudited standalone and consolidated financial results and an Employee Stock Option Scheme. The auditor's report highlighted ongoing SFIO and EOW investigations, alleged improper transactions, and a Supreme Court order for a potential forensic audit into past transactions.
Financials
Negative
2026-02-13 18:51
CRITICAL RED FLAG DETECTED
Board approved Q3 FY26 standalone results, ESOP 2026, and revised RPT policy. The filing notes ongoing SFIO investigation and Supreme Court's direction for a potential forensic audit regarding past transactions and the IHH acquisition, raising significant regulatory and legal concerns.
Business Update
Neutral
2026-02-06 13:54
Fortis Healthcare Limited announced an Investors/Analysts' conference call on Monday, February 16, 2026, at 11:00 am IST to discuss the company's unaudited financial results for the quarter ended December 31, 2025. Dial-in and replay details are provided in the filing.